Immune12 Overview

coral-reef-11
coral-reef-11-mobile

Bringing the anti-tumor potential of marine-life to the forefront of innovative glioblastoma research.

Immune12 is a proprietary complex biologic derived from specific marine-sourced ingredients that may have potential anticancer properties based on preclinical studies and limited early phase human trials. If you would like more information, please contact us at info@pacificmarinebiotech.com.

We have received a pre-IND number from the FDA and plan to submit an investigational new drug application (IND) in 2024 for approval to launch clinical trials for testing on humans with glioblastoma and diffuse pontine glioma (DIPG).

Are you a medical professional looking for more information on Immune12? If so, click here.

Our Pipeline

PMB Pipeline-2024-02-28

Frequently Asked Questions

How is Immune12 administered?

Immune12 is taken orally, best if mixed with fruit juice or a non-alcoholic beverage. It can also be administered through a feeding tube or sipped through a straw.

Who is the manufacturer of Immune12?

The manufacturer of Immune12 is Unicorn Pacific Marketing, based out of Vanuatu. To learn more about our manufacturer’s sustainability initiatives, please contact us at info@pacificmarinebiotech.com.

Can I take Immune12 alongside chemotherapy?

No adverse side effects have been reported from patients taking Immune12 concurrently with standard of care.

Does Immune12 have any toxicity?

Toxicity studies show that Immune12 has zero toxicity, even at high doses.

What are the side effects of Immune12?

There are currently no reported adverse side effects of Immune12. Some users may experience mild diarrhea during their first few days of use. People who are allergic to shellfish should consult their physician before taking Immune12.

Is expanded access available for Immune12?

Expanded access for Immune12 is currently unavailable. Please sign up for our newsletter for updates on clinical trials and our expanded access program.

Published Journal Articles

adobe-icon

Effect of TBL-12 on Proliferation, Migration, Invasion, and Apoptosis of Gastric Cancer Cell HGC-27

adobe-icon

Nova Southeastern University | NSU Florida, Vivarium Core – TBL-12 Fixed Dose Study

adobe-icon

Suppression of Human Multiple Myeloma Cell Growth by TBL-12 in Combination with low doses of Velcade: Insight into the modulation of IL-6/STAT-3 mechanisms

adobe-icon

2018 British Journal of Haematology – A phase II trial of TBL-12 sea cucumber extract in patients with untreated asymptomatic myeloma

adobe-icon

Sea cucumber extract TBL‐12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen‐activated protein kinase and intrinsic caspase apoptosis pathway

Contact Us

If you cannot find the answer to your question, please contact Pacific Marine Biotech by filling out the following form.